Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
Adil Yousaf, Pharmacy Manager at Green Health Co., shared a post on LinkedIn:
“Thrombolysis is among the most time-critical treatments in medicine but speed never replaces eligibility screening.
Thrombolytics, also called fibrinolytics, accelerate conversion of plasminogen to plasmin, which breaks down fibrin within an existing clot.
They are not interchangeable:
- Alteplase (Activase or Actilyse) is a recombinant tissue plasminogen activator. US labeling includes acute ischemic stroke, acute myocardial infarction and selected acute massive pulmonary embolism.
- Tenecteplase (TNKase or Metalyse) is a modified tPA. Current US and EU authorizations include acute ischemic stroke and STEMI, but labeled time windows and product presentations differ. The 2026 AHA/ASA stroke guideline endorses either alteplase or tenecteplase for eligible patients in the 4.5-hour thrombolytic window.
- Reteplase (Retavase) has a US STEMI indication.
- Urokinase (Kinlytic) has US labeling for selected acute massive pulmonary embolism; current availability must be confirmed locally.
The essential safety pearl is catastrophic bleeding prevention. Before treatment, confirm the diagnosis and review brain imaging when stroke is suspected, blood pressure, bleeding history, recent surgery or trauma, antiplatelet and anticoagulant exposure, and relevant laboratory results.
Which thrombolytic eligibility check is most often delayed or overlooked?
Educational content only not individualized medical advice.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage
-
Oct 10, 2026, 02:17Dino Mehic: Managing Heavy Menstrual Bleeding in Patients with BDUC
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia